NCT03022331 is a clinical trial in Aortitis, sponsored by University of Pennsylvania.

Who is sponsoring NCT03022331?

NCT03022331 is sponsored by University of Pennsylvania.

Is NCT03022331 still recruiting?

NCT03022331 is currently completed. Last updated 11 May 2020.

Last reviewed 2020-05-11 · How we verify

NCT03022331

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VCRC Longitudinal Protocol for Aortitis

Completed Last updated 11 May 2020

What this trial tests

trial in Aortitis in 16 participants. Completed in 1 September 2019.

Timeline

4 December 2017

Primary endpoint
1 September 2019

1 September 2019

Quick facts

Lead sponsor	University of Pennsylvania
Status	Completed
Study type	OBSERVATIONAL
Enrollment	16
Start date	4 December 2017
Primary completion	1 September 2019
Estimated completion	1 September 2019
Sites	10 locations across Canada, United States

Conditions studied

Aortitis — all drugs for Aortitis →

Sponsor

University of Pennsylvania

Who can join

5 and older, any sex, with Aortitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The term 'aortitis' refers to inflammation of the aorta. Aortitis is known to occur in a variety of vasculitides and connective tissue diseases, such as giant cell arteritis (GCA), Takayasu arteritis (TAK), rheumatoid arthritis, and spondyloarthropathies, among others. This study will establish a longitudinal cohort for these diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Aortitis

Currently open trials in the same condition.

NCT06271018 — TocILizumab in aorTitis in GCA (TILT) · recruiting
NCT06866535 — VIP - Vascular Infection Project · recruiting

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03022331 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 11 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03022331.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing